Tulmimetostat | 2567686-02-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Tulmimetostat
• 英文别名: (2R)-7-chloro-2-[4-(3-methoxyazetidin-1-yl)cyclohexyl]-2,4-dimethyl-N-[(6-methyl-4-methylsulfanyl-2-oxo-1H-pyridin-3-yl)methyl]-1,3-benzodioxole-5-carboxamide
• CAS: 2567686-02-4
• 化学式: C₂₈H₃₆ClN₃O₅S
• 分子量: 562.1
• InChiKey: CAAWBLRXQXMGHV-WOLMIXIISA-N

物化性质

• 沸点：
  653.6±55.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] CRYSTALLINE FORMS OF 7-CHLORO-2-(4-(3-METHOXYAZETIDIN-1-YL)CYCLOHEXYL)-2,4-DIMETHYL-N-((6-METHYL-4-(METHYLTHIO)-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)BENZO[D][1,3]DIOXOLE-5-CARBOXAMIDE<br/>[FR] FORMES CRISTALLINES DE 7-CHLORO-2-(4-(3-MÉTHOXYAZÉTIDINE-1-YL))CYCLOHEXYL) 2,4-DIMÉTHYL-N-((6-MÉTHYL-4-(MÉTHYLTHIO)-2-OXO-1,2-DIHYDROPYRIDINE-3-YL) MÉTHYL)BENZO[D][1,3]DIOXOLE-5-CARBOXAMIDE
  申请人：CONSTELLATION PHARMACEUTICALS INC

  公开号：WO2021016414A1

  公开（公告）日：2021-01-28

  The present disclosure relates to a crystalline Form 1 of 7-chloro-2-(4-(3- methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2- dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, which is useful as modulators the activity of histone methyl modifying enzymes. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline form and methods of using said compositions in the treatment of various disorders.

  本公开涉及7-氯-2-(4-(3-甲氧基氮杂环戊烷-1-基)环己基)-2,4-二甲基-N-((6-甲基-4-(甲硫基)-2-氧代-1,2-二氢吡啶-3-基)甲基)苯并[d][1,3]二噁烷-5-羧酰胺的晶型1，该晶型对组蛋白甲基修饰酶的活性具有调节作用。本公开还提供了包含该晶型的药学上可接受的组合物，并提供了使用该组合物治疗各种疾病的方法。
• EZH2 INHIBITION IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS
  申请人：Constellation Pharmaceuticals, Inc.

  公开号：US20220257577A1

  公开（公告）日：2022-08-18

  Provided herein are methods for treating advanced relapsed solid tumors using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2, 4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide; or a pharmaceutically acceptable salt thereof. Also provided herein are methods of treating cancers (e.g., solid tumors) using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide; or a pharmaceutically acceptable salt thereof; and a second agent selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor.
• [EN] EZH2 INHIBITION IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCERS<br/>[FR] INHIBITION D'EZH2 DANS DES POLYTHÉRAPIES POUR LE TRAITEMENT DE CANCERS
  申请人：CONSTELLATION PHARMACEUTICALS INC

  公开号：WO2021016409A1

  公开（公告）日：2021-01-28

  Provided herein are methods for treating advanced relapsed solid tumors using 7- chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2, 4-dimethyl -N-((6-methyl-4-(methylthio)- 2-oxo-l,2-dihydropyridin-3-yl)methyl)benzo[d][l,3]dioxole-5-carboxamide; or a pharmaceutically acceptable salt thereof. Also provided herein are methods of treating cancers (e.g., solid tumors) using 7-chloro-2-(4-(3-methoxyazetidin-l-yl)cyclohexyl)-2,4- dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-l,2-dihydropyri din-3- yl)methyl)benzo[d][1,3]dioxole-5-carboxamide; or a pharmaceutically acceptable salt thereof; and a second agent selected from a topoisomerase inhibitor, a DNA alkylating agent, and an androgen receptor signaling inhibitor.